Z0153
ZM 241385
≥98% (HPLC), adenosine A2A antagonist, powder
Sinónimos:
4-(-2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3-a} {1,3,5}triazin-5-yl-amino]ethyl)phenol
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Fórmula empírica (notación de Hill):
C16H15N7O2
Número CAS:
Peso molecular:
337.34
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
ZM 241385, ≥98% (HPLC)
SMILES string
Nc1nc(NCCc2ccc(O)cc2)nc3nc(nn13)-c4ccco4
InChI key
PWTBZOIUWZOPFT-UHFFFAOYSA-N
InChI
1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO: >15 mg/mL
storage temp.
room temp
Quality Level
Biochem/physiol Actions
ZM 241385 is a potent selective adenosine A2A antagonist.
ZM 241385 is a potent selective adenosine A2A antagonist. The A2A receptor plays a role in regulating myocardial oxygen consumption and coronary blood flow and is highly expressed in the brain, where it has important roles in the regulation of glutamate and dopamine release. ZM 241385 has neuroprotective effects and is being investigated for use in Parkinson′s and other neurodegenerative disorders.
Features and Benefits
This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Krystyna Gołembiowska et al.
Neurotoxicity research, 22(2), 150-157 (2012-03-13)
It has been shown that a decreased vesicular monoamine transporter (VMAT2) function and the disruption of dopamine (DA) storage is an early contributor to oxidative damage of dopamine neurons in Parkinson's disease (PD). In our previous study, we demonstrated that
Sergey Ryzhov et al.
Journal of the American Heart Association, 8(13), e010874-e010874 (2019-06-27)
Background Patients resuscitated from cardiac arrest ( CA ) have highly variable neurological, circulatory, and systemic ischemia-reperfusion injuries. After the initial hypoxic-ischemic insult, a cascade of immune and inflammatory responses develops and is often fatal. The role of the immune
Fabrizio Vincenzi et al.
PloS one, 7(6), e39317-e39317 (2012-07-05)
A(3) adenosine receptors (ARs) play a pivotal role in the development of cancer and their activation is involved in the inhibition of tumor growth. The effects of pulsed electromagnetic fields (PEMFs) on cancer have been controversially discussed and the detailed
Ajith A Welihinda et al.
Cellular signalling, 28(6), 552-560 (2016-02-24)
Inosine is an endogenous purine nucleoside that is produced by catabolism of adenosine. Adenosine has a short half-life (approximately 10s) and is rapidly deaminated to inosine, a stable metabolite with a half-life of approximately 15h. Resembling adenosine, inosine acting through
Tarek K Motawi et al.
Molecular and cellular biochemistry, 465(1-2), 89-102 (2019-12-11)
Parkinson's disease (PD) is the second common age-related neurodegenerative disease. It is characterized by control loss of voluntary movements control, resting tremor, postural instability, bradykinesia, and rigidity. The aim of the present work is to evaluate curcumin, niacin, dopaminergic and
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico